These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25073863)

  • 1. Mantle cell lymphoma: a great masquerader.
    Paludo J; Kapoor P; Oliveira JL; Garrity JA; Nowakowski GS
    Int J Hematol; 2014 Oct; 100(4):313-4. PubMed ID: 25073863
    [No Abstract]   [Full Text] [Related]  

  • 2. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
    Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
    Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphomatous polyposis as primary manifestation of mantle cell lymphoma.
    Yu SC; Liu KL; Chang LC
    Eur J Haematol; 2012 Aug; 89(2):185-6. PubMed ID: 22563740
    [No Abstract]   [Full Text] [Related]  

  • 4. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
    Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
    J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinib.
    Pang A; Au-Yeung R; Leung RYY; Kwong YL
    Ann Hematol; 2019 Oct; 98(10):2433-2436. PubMed ID: 31446456
    [No Abstract]   [Full Text] [Related]  

  • 6. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
    Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in Japan.
    Miura K; Takasaki H; Tsujimura H; Kanno M; Maeda Y; Tomita N; Takai K; Masaki Y; Takizawa J; Mori H; Terasaki Y; Yoshida T; Takeuchi J; Motomura S
    Int J Hematol; 2011 May; 93(5):684-686. PubMed ID: 21479980
    [No Abstract]   [Full Text] [Related]  

  • 8. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
    Karmali R; Larson ML; Wooldridge JE; Gregory SA; O'Brien T; Shammo JM; Bueschel K; Venugopal P
    Leuk Lymphoma; 2011 Nov; 52(11):2097-104. PubMed ID: 21702643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The epigenetics of mantle cell lymphoma.
    Yu M; Epner E
    Curr Treat Options Oncol; 2007 Oct; 8(5):375-81. PubMed ID: 18214689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.
    Smith MR; Li H; Gordon L; Gascoyne RD; Paietta E; Forero-Torres A; Kahl BS; Advani R; Hong F; Horning SJ
    J Clin Oncol; 2012 Sep; 30(25):3119-26. PubMed ID: 22851557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboembolic events during treatment with thalidomide.
    Urbauer E; Kaufmann H; Nösslinger T; Raderer M; Drach J
    Blood; 2002 Jun; 99(11):4247-8. PubMed ID: 12043695
    [No Abstract]   [Full Text] [Related]  

  • 12. Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue.
    Salhotra A; Shan Y; Tsai NC; Sanchez JF; Aldoss I; Ali H; Paris T; Spielberger R; Cao TM; Nademanee A; Forman SJ; Chen R
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1264-1268. PubMed ID: 28434928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical analysis of 140 cases of mantle cell lymphoma].
    Hu MW; Lou YJ; Yang M; Wang HF; Wang L; Jin J
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):390-395. PubMed ID: 29860768
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe acute thrombocytopenia following rituximab therapy.
    Rosado M; Chao H; Rose M
    Leuk Lymphoma; 2007 Nov; 48(11):2239-40. PubMed ID: 17926181
    [No Abstract]   [Full Text] [Related]  

  • 15. What is your diagnosis? Cutaneous B-cell lymphoma.
    Carlson SW; Aneja S; Honda K; Cooper KD
    Cutis; 2014 Nov; 94(5):217, quiz 249-51. PubMed ID: 25474456
    [No Abstract]   [Full Text] [Related]  

  • 16. Complete and durable remission of refractory mantle cell lymphoma with repeated rituximab monotherapy.
    Ishiyama K; Takami A; Okumura H; Ozaki J; Shimadoi S; Yamanaka S; Nakao S
    Int J Hematol; 2005 May; 81(4):319-22. PubMed ID: 15914363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraocular lymphoma as relapse after chemotherapy for primary breast diffuse large B-cell lymphoma.
    Matsuo T; Tanaka T; Yano T
    J Clin Exp Hematop; 2018 Dec; 58(4):180-183. PubMed ID: 30416173
    [No Abstract]   [Full Text] [Related]  

  • 18. Intravascular large B cell lymphoma: widespread but not everywhere.
    Ponzoni M; Ferreri AJ
    Acta Haematol; 2014; 131(1):16-7. PubMed ID: 24021531
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
    Till BG; Li H; Bernstein SH; Fisher RI; Burack WR; Rimsza LM; Floyd JD; DaSilva MA; Moore DF; Pozdnyakova O; Smith SM; LeBlanc M; Friedberg JW
    Br J Haematol; 2016 Jan; 172(2):208-18. PubMed ID: 26492567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.
    Delarue R; Haioun C; Ribrag V; Brice P; Delmer A; Tilly H; Salles G; Van Hoof A; Casasnovas O; Brousse N; Lefrere F; Hermine O;
    Blood; 2013 Jan; 121(1):48-53. PubMed ID: 22718839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.